-
公开(公告)号：KR101256273B1
公开(公告)日：2013-04-18
申请号：KR1020100066136
申请日：2010-07-09
Applicant: 성균관대학교산학협력단
Abstract: 본 발명은 목단피(Moutan Radicis
Cortex) 추출물을 포함하는 간질환 예방 또는 치료용 조성물에 관한 것이다. 또한 본 발명은 목단피 추출물을 유효성분으로 포함하는 간질환 개선용 식품 조성물에 관한 것이다.-
公开(公告)号：KR1020120088610A
公开(公告)日：2012-08-08
申请号：KR1020120010081
申请日：2012-01-31
Applicant: 성균관대학교산학협력단
IPC: A61K31/216 , A61K31/045 , A61K31/352 , A61P1/00
CPC classification number: A61K31/216
Abstract: PURPOSE: A composition containing chlorogenic acid and a derivative thereof is provided to reduce histological change of inflammatory cells and to prevent or treat gastroesophageal reflux disorder without side effect. CONSTITUTION: A pharmaceutical composition for preventing or treating gastroesophageal reflux disorder contains chlorogenic acid or pharmaceutically acceptable salt or derivative thereof. The pharmaceutical composition additionally contains pharmaceutically acceptable carriers, excipient, or diluent. The salt is sodium is chlorogenic acid sodium or chlorogenic acid potassium. The derivative is 4-caffeoylquinic acid, 5-caffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, 3-feruloylquinic acid, 4-feruloylquinic acid, 5-feruloylquinic acid, or 3-feruloyl-4-caffeoylquinic acid. A food composition for preventing or treating gastroesophageal reflux disorder contains chlorogenic acid, salt, or derivative.
Abstract translation: 目的：提供含有绿原酸及其衍生物的组合物，以减少炎性细胞的组织学变化并预防或治疗胃食管反流障碍而无副作用。 构成：用于预防或治疗胃食管反流病的药物组合物含有绿原酸或其药学上可接受的盐或衍生物。 药物组合物另外含有药学上可接受的载体，赋形剂或稀释剂。 盐是钠是绿原酸钠或绿原酸钾。 衍生物是4-咖啡酰奎尼酸，5-咖啡酰奎尼酸，3,4-二脱酰奎宁酸，3,5-二茄酸奎宁酸，4,5-二脱氧奎尼酸，3-阿魏酰奎尼酸，4-阿魏酰奎尼酸，5-阿魏酰奎尼酸或 3-阿魏酰-4-咖啡酰奎宁酸。 用于预防或治疗胃食管反流病症的食物组合物含有绿原酸，盐或衍生物。
-
公开(公告)号：KR100876979B1
公开(公告)日：2009-01-07
申请号：KR1020070057430
申请日：2007-06-12
Applicant: 성균관대학교산학협력단
IPC: A61K36/886 , A61P7/08
Abstract: 본 발명은 알로에 추출물을 유효성분으로 하는 패혈증 및 패혈증성 쇼크 치료용 약학 조성물로서, 천연물을 소재로 한 치료제이므로 부작용이 적으면서, 패혈증으로 인한 장기의 손상과 관련된 다장기기능부전증후군(multiple organ dysfunction syndrome)을 억제하여 사망률을 낮춤으로써 패혈증 및 패혈증성 쇼크의 치료에 효과적으로 이용될 수 있다.
알로에, 패혈증, 패혈증성 쇼크, 다장기기능부전증후군(multiple organ dysfunction syndrome)-
公开(公告)号：KR1020080109293A
公开(公告)日：2008-12-17
申请号：KR1020070057430
申请日：2007-06-12
Applicant: 성균관대학교산학협력단
IPC: A61K36/886 , A61P7/08
Abstract: A pharmaceutical composition comprising the aloe extract is provided to treat the sepsis and septic shock without reduced side effects which frequently show up in the chemical substance due to use of natural products. The pharmaceutical composition for treating the sepsis and the septic shock comprises the aloe extract as the active ingredient, wherein the aloe is Aloe vera, and suppress the damage of internal organs due to the sepsis, wherein the internal organs include liver and bowels, the kidneys and heart.
Abstract translation: 提供包含芦荟提取物的药物组合物以治疗败血症和败血性休克，而不会由于使用天然产物而频繁出现在化学物质中的副作用降低。 用于治疗败血症和败血性休克的药物组合物包括芦荟提取物作为活性成分，其中芦荟是芦荟，并且抑制由于败血症引起的内部器官损伤，其中内脏包括肝和肠，肾脏 和心。
-
公开(公告)号：KR101759436B1
公开(公告)日：2017-07-19
申请号：KR1020160046477
申请日：2016-04-15
Applicant: 성균관대학교산학협력단
CPC classification number: A61K36/53 , A23L33/105 , A23V2002/00 , A61K2236/33 , A61K2236/331 , A61K2236/333 , A61P1/16 , A61P35/00
Abstract: 본발명은간 질환의예방또는치료에유용하게사용될수 있는광곽향 () 추출물을포함하는조성물에관한것이다. 본발명의광곽향추출물을이용하여혈중 ALT, IL-6 농도및 간장내 TLR 4 단백질발현양을효과적으로감소시킬수 있음을구체적으로확인하였는바, 간질환의예방또는치료에있어서, 보다근본적으로접근하여타겟치료를할 수있을것으로기대된다.
Abstract translation: 本发明涉及包含用于预防或治疗肝脏疾病的光学活性提取物（）的组合物。 已经证实，通过使用本发明的提取物可以有效地降低肝中的ALT，IL-6浓度和TLR4蛋白质表达水平，并且已经发现肝病的预防和治疗可以更根本地 预期有针对性的治疗是可能的。
-
Patent Agency Ranking
公开(公告)号：KR1020170045710A
公开(公告)日：2017-04-27
申请号：KR1020160119284
申请日：2016-09-19
Applicant: 성균관대학교산학협력단
CPC classification number: A61K36/65 , A23L33/105 , A23V2002/00 , A23V2200/30
Abstract: 본발명은간질환의예방또는치료에유용하게사용될수 있는목단피 () 추출물의분획물을포함하는조성물에관한것이다. 본발명에서는상기조성물을이용하여혈중 ALT 농도를효과적으로감소시키고, 간장내 TLR4 또는 IL-1β단백질발현의증가를억제시키며, 간장내 지질과산화또한억제시킬수 있음을구체적으로확인하였는바, 간질환의예방또는치료에있어서, 보다근본적으로접근하여타겟치료할수 있을것으로기대된다.
Abstract translation: 本发明涉及一种组合物，其包含可有效用于预防或治疗肝病的桑（提取物的一部分。 在本发明中，使用该组合物有效地降低血清ALT水平，肝内TLR4或IL-1β蛋白sikimyeo抑制表达的增加，肝脏脂质过氧化还预防横杆，hayeotneun确认具体而言，是sikilsu抑制病 或治疗，预计能够更有效地接近目标。
-
公开(公告)号：KR1020160137364A
公开(公告)日：2016-11-30
申请号：KR1020160046477
申请日：2016-04-15
Applicant: 성균관대학교산학협력단
CPC classification number: A61K36/53 , A23L33/105 , A23V2002/00 , A61K2236/33 , A61K2236/331 , A61K2236/333 , A61P1/16 , A61P35/00
Abstract: 본발명은간 질환의예방또는치료에유용하게사용될수 있는광곽향 () 추출물을포함하는조성물에관한것이다. 본발명의광곽향추출물을이용하여혈중 ALT, IL-6 농도및 간장내 TLR 4 단백질발현양을효과적으로감소시킬수 있음을구체적으로확인하였는바, 간질환의예방또는치료에있어서, 보다근본적으로접근하여타겟치료를할 수있을것으로기대된다.
-
公开(公告)号：KR1020120025800A
公开(公告)日：2012-03-16
申请号：KR1020100087924
申请日：2010-09-08
Applicant: 성균관대학교산학협력단
CPC classification number: A61K31/352
Abstract: PURPOSE: A pharmaceutical composition containing genipin or derivatives thereof are provided to treat sepsis and to reduce side effect. CONSTITUTION: A pharmaceutical composition for preventing or treating sepsis contains genipin or derivatives thereof. The derivatives are geniposide, genipiodisic acid, penta-acetyl geniposide, 6alpha-hydroxygeniposide, 6beta-dhydroxygeniposide, 6alpha-methoxygeniposide, or 6beta-methoxygeniposide. The composition additionally contains pharmaceutically acceptable carrier, excipient, or diluent.
Abstract translation: 目的：提供含有京尼芬或其衍生物的药物组合物以治疗败血症并减少副作用。 构成：用于预防或治疗败血病的药物组合物含有京尼平或其衍生物。 衍生物为栀子苷，天敌碘酸，五乙酰栀子苷，6α-羟基脯氨酸，6β-二羟基脯氨酸，6α-甲氧基脯氨酸或6β-甲氧基脯氨酸。 该组合物另外含有药学上可接受的载体，赋形剂或稀释剂。
-
19.发明公开
公开(公告)号：KR1020100096566A
公开(公告)日：2010-09-02
申请号：KR1020090015488
申请日：2009-02-24
Applicant: 주식회사 유니베라 , 성균관대학교산학협력단
IPC: A61K36/886 , A61P1/16 , A61K36/185 , A23L1/30
Abstract: PURPOSE: A medicinal composition for preventing or treating liver diseases containing processed aloe vera extract is provided to suppress liver fibrosis, fatty liver, hepatitis. CONSTITUTION: A medicinal composition for preventing or treating liver diseases contains processed aloe vera extract as an active ingredient. The medicinal composition additionally contains milk thistle. The weight ratio of the aloe vera extract and milk thistle is 1:0.1-1. A method for producing the processed aloe vera extract comprises: a step of extracting aloe vera leaves with a solvent to obtain aloe vera extract; a step of filtering and concentrating the extract; a step of heating the concentrate at 60-100°C for 1-30 minutes; and a step of freeze-drying.
Abstract translation: 目的：提供一种预防或治疗含有加工芦荟提取物的肝脏疾病的药物组合物，用于抑制肝纤维化，脂肪肝，肝炎。 构成：用于预防或治疗肝脏疾病的药物组合物含有经加工的芦荟提取物作为活性成分。 药用组合物另外含有乳蓟。 芦荟提取物和乳蓟的重量比为1：0.1-1。 一种加工芦荟提取物的制备方法，其特征在于：用溶剂提取芦荟叶以获得芦荟提取物的步骤; 过滤和浓缩提取物的步骤; 在60-100℃下加热浓缩物1-30分钟的步骤; 和冷冻干燥步骤。
-
公开(公告)号：KR1020090071871A
公开(公告)日：2009-07-02
申请号：KR1020070139802
申请日：2007-12-28
Applicant: 성균관대학교산학협력단
IPC: A61K31/19 , A61K31/185 , A61P31/00
CPC classification number: A61K31/19
Abstract: A pharmaceutical composition for treating sepsis and septic shock is provided to suppress multiple organ dysfunction syndrome related to organ damage and lower mortality. A pharmaceutical composition for treating sepsis and septic shock comprises a compound of the chemical formula 1 or its pharmaceutically allowable salt as an active ingredient. In the chemical formula 1, R1, R2, and R3 are hydrogen, or residue of the chemical formula 2. In the chemical formula 1, R4 is hydrogen, alkyl group of 1-6 carbon atoms. The compound of the chemical formula 1 is chlorogenic acid, and comprises 3-caffeoylquinic acid, 4-caffeoylquinic acid, 5-caffeoylquinic acid, 3,4-caffeoylquinic acid, 3,5-caffeoylquinic acid, or 4,5-dicaffeoylquinic acid. The pharmaceutical composition suppresses organic damage by the sepsis. The organ is liver, kidney, or heart. The pharmaceutical composition further comprises carrier, excipient, or diluents.
Abstract translation: 提供用于治疗败血症和败血性休克的药物组合物，以抑制与器官损伤相关的多器官功能障碍综合征和降低死亡率。 用于治疗败血症和败血性休克的药物组合物包含化学式1的化合物或其药学上可允许的盐作为活性成分。 在化学式1中，R 1，R 2和R 3是氢或化学式2的残基。在化学式1中，R 4是氢，1-6个碳原子的烷基。 化学式1的化合物是绿原酸，并且包含3-咖啡酰奎尼酸，4-咖啡酰奎尼酸，5-咖啡酰奎尼酸，3,4-咖啡酰奎尼酸，3,5-咖啡酰奎尼酸或4,5-二脱氧奎尼酸。 药物组合物抑制败血症的有机损伤。 器官是肝脏，肾脏或心脏。 药物组合物还包含载体，赋形剂或稀释剂。
-
-
-
-
-
-
-
-
-
Search Results
25
records
(took 0.026 seconds)
